Posted by
Paul Fletcher
0 Comments
NTI generics require stricter regulation than standard generics due to narrow margins between effective and toxic doses. This article explores how the FDA, EMA, Canada, and Japan differ in their approaches, what’s changing in 2025, and why prescribers must stay cautious.
read more